Key messages What is known • Anti-dopaminergic agents (metoclopramide (MCP), trimethobenzamide (TMB), and domperidone (DOM)) are used for diabetic gastroparesis, but their effects on diabetic eye are not well studied. What is new • These drugs do not affect intraocular pressure or tear production in diabetic rats. • They increase retinal prolactin receptor expression and reduce VEGF and CD31 immunoreactivity, indicating modulation of angiogenesis-related markers in the diabetic retina. • These findings may encourage future research to explore the potential role of prolactin-elevating antidopaminergic agents in diabetic retinopathy.
Peker et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: